In chronic myeloid leukemia (CML) cells, depletion of ZFP36L1 leads to decreased proliferation of CML cells upon treatment with tyrosine kinase inhibitor, while ZFP36L1 directly inhibits CDKN1A expression via post-transcriptional regulation [31]. Here, ZFP36L1 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.